Plinabulin
Non-Small Cell Lung Cancer (NSCLC)
Key Facts
About BeyondSpring
BeyondSpring is dedicated to developing novel cancer treatments, with its core technology platform based on the small-molecule drug plinabulin, a selective immunomodulating microtubule-binding agent. The company's most advanced program is plinabulin for the prevention of chemotherapy-induced neutropenia (CIN), which has undergone Phase 3 clinical trials. BeyondSpring's strategy involves leveraging plinabulin's dual mechanism of action—protecting bone marrow and activating T-cells—to improve outcomes in cancer care and expand into broader immuno-oncology applications.
View full company profileAbout BeyondSpring
BeyondSpring is dedicated to developing novel cancer treatments, with its core technology platform based on the small-molecule drug plinabulin, a selective immunomodulating microtubule-binding agent. The company's most advanced program is plinabulin for the prevention of chemotherapy-induced neutropenia (CIN), which has undergone Phase 3 clinical trials. BeyondSpring's strategy involves leveraging plinabulin's dual mechanism of action—protecting bone marrow and activating T-cells—to improve outcomes in cancer care and expand into broader immuno-oncology applications.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| NBTXR3 + anti-PD1 | Nanobiotix | Phase 1 |
| TTFields | Novocure | Phase 3 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1/2 |
| VAC2 | Lineage Cell Therapeutics | Phase 1 |
| TG6050 | Transgene SA | Preclinical |
| Monalizumab (IPH2201) | Innate Pharma | Phase 3 |
| PD1-Vaxx (IMU-201) | Imugene | Phase 1 |
| ATNM-400 | Actinium Pharmaceuticals | Preclinical |
| Reqorsa® (quaratusugene ozeplasmid) + Keytruda® (pembrolizumab) | Genprex | Phase 1/2 |
| ABD-3001 | Advanced Biodesign | Phase 1 |